Skip to main content
Journal cover image

A Qualitative Study to Assess US Patient Preferences between new Transdermal System and Injectable Anabolic Therapies for Osteoporosis Treatment.

Publication ,  Journal Article
Beaudart, C; Silverman, S; Gold, DT; Williams, SA; Weiss, R; Hiligsmann, M
Published in: Arch Osteoporos
April 4, 2022

UNLABELLED: US patients with osteoporosis included in three focus groups identified efficacy, safety, cost, and convenience as important attributes of treatment when choosing between anabolic therapies with high stated preference for the solid Microstructured Transdermal System. OBJECTIVE: The current study evaluated patient perspective and relative importance of treatment attributes of in-home daily self-administration of abaloparatide-solid Microstructured Transdermal System (sMTS) compared with other anabolic agents (i.e. in-home daily subcutaneous self-injections, and monthly subcutaneous injections at doctor office) among a group of US patients with osteoporosis. METHODS: The current study included systematic literature reviews, experts' consultation and three online patients focus groups (n=27), including patients ≥50 years of age at high risk for fracture. Nominal Group Technique was used by asking patients to (1) Individually identify characteristics that would be important for them when choosing between anabolic treatments, (2) Share ideas and discuss perspectives with other patients, (3) Review additional attributes generated from a systematic literature review, (4) Select and rank individually the 7 most important characteristics from the list and (5) Report their acceptability and stated preference ranking between the three treatment options. RESULTS: Twenty women and 7 men with a mean age of 65 (range 51-85 years) participated in the focus groups. Twenty-four treatment characteristics were identified through focus groups and literature review. Efficacy, safety, out-of-pocket costs, strength of evidence and the option to self-administer were ranked as the most important attributes. The majority of patients stated preference for a daily sMTS if prescribed by their doctor. CONCLUSIONS: This study revealed that efficacy, safety, costs, and convenience are important attributes of osteoporosis treatment for US patients at high risk for fractures when choosing between anabolic therapies, with a high stated preference for sMTS.

Duke Scholars

Published In

Arch Osteoporos

DOI

EISSN

1862-3514

Publication Date

April 4, 2022

Volume

17

Issue

1

Start / End Page

57

Location

England

Related Subject Headings

  • Qualitative Research
  • Patient Preference
  • Osteoporosis
  • Middle Aged
  • Male
  • Injections, Subcutaneous
  • Humans
  • Fractures, Bone
  • Female
  • Aged, 80 and over
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Beaudart, C., Silverman, S., Gold, D. T., Williams, S. A., Weiss, R., & Hiligsmann, M. (2022). A Qualitative Study to Assess US Patient Preferences between new Transdermal System and Injectable Anabolic Therapies for Osteoporosis Treatment. Arch Osteoporos, 17(1), 57. https://doi.org/10.1007/s11657-022-01075-z
Beaudart, Charlotte, Stuart Silverman, Deborah T. Gold, Setareh A. Williams, Rich Weiss, and Mickael Hiligsmann. “A Qualitative Study to Assess US Patient Preferences between new Transdermal System and Injectable Anabolic Therapies for Osteoporosis Treatment.Arch Osteoporos 17, no. 1 (April 4, 2022): 57. https://doi.org/10.1007/s11657-022-01075-z.
Beaudart C, Silverman S, Gold DT, Williams SA, Weiss R, Hiligsmann M. A Qualitative Study to Assess US Patient Preferences between new Transdermal System and Injectable Anabolic Therapies for Osteoporosis Treatment. Arch Osteoporos. 2022 Apr 4;17(1):57.
Beaudart, Charlotte, et al. “A Qualitative Study to Assess US Patient Preferences between new Transdermal System and Injectable Anabolic Therapies for Osteoporosis Treatment.Arch Osteoporos, vol. 17, no. 1, Apr. 2022, p. 57. Pubmed, doi:10.1007/s11657-022-01075-z.
Beaudart C, Silverman S, Gold DT, Williams SA, Weiss R, Hiligsmann M. A Qualitative Study to Assess US Patient Preferences between new Transdermal System and Injectable Anabolic Therapies for Osteoporosis Treatment. Arch Osteoporos. 2022 Apr 4;17(1):57.
Journal cover image

Published In

Arch Osteoporos

DOI

EISSN

1862-3514

Publication Date

April 4, 2022

Volume

17

Issue

1

Start / End Page

57

Location

England

Related Subject Headings

  • Qualitative Research
  • Patient Preference
  • Osteoporosis
  • Middle Aged
  • Male
  • Injections, Subcutaneous
  • Humans
  • Fractures, Bone
  • Female
  • Aged, 80 and over